Ubrelvy release date?

Ubrelvy (ubrogepant) was approved by the U.S. Food and Drug Administration (FDA) on December 23, 2019 [1].

How soon after approval was Ubrelvy available to patients?

Ubrelvy became available for prescription in the United States in the first quarter of 2020 [2].

What is Ubrelvy used for?

Ubrelvy is a prescription medication used for the acute treatment of migraine with or without aura in adults [1]. It is not used to prevent migraines or to treat other types of headaches [1].

How does Ubrelvy work?

Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the action of CGRP, a molecule that is thought to play a role in migraine [3].

What is the difference between Ubrelvy and other migraine treatments?

Unlike triptans, which constrict blood vessels, Ubrelvy does not constrict blood vessels [1]. This makes it an option for patients who cannot take triptans due to cardiovascular risks [1].

When does Ubrelvy's patent protection expire?

Information on specific patent expiry dates for Ubrelvy can be found on DrugPatentWatch.com [4]. DrugPatentWatch.com tracks patent data and exclusivity periods for pharmaceuticals, which can indicate when generic versions might become available [4].